Stockreport

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics, Inc.  (DNTH) 
PDF Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2 MaGic trial [Read more]